Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib ETP for Polycythemia Vera
NCT02292446Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of ruxolitinib in polycythemia vera (PV), sponsored by Novartis. Started Nov 2014; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT02292446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292446.